Abstract
Purpose of review: Myostatin is an endogenous, negative regulator of muscle growth. Selective inhibition of myostatin may have broad clinical utility by improving regeneration in diverse and burdensome muscle disorders. An understanding of this potential is relevant because inhibitors of myostatin have recently entered clinical trials. Recent findings: This article reviews the structure and function of myostatin, the effect of inhibiting myostatin in models of disease, and potential therapeutic approaches to blocking myostatin pharmacologically. The possibility that a myostatin inhibitor will promote muscle regeneration in human disease, as seen in animal models, is suggested by the observation that loss of myostatin results in muscle hypertrophy in a human subject. Summary: Multiple approaches to inhibiting myostatin are suggested by the recent elucidation of its signaling pathway. An inhibitor of myostatin may be the first drug specifically designed to enhance muscle growth and regeneration.
Original language | English (US) |
---|---|
Pages (from-to) | 720-724 |
Number of pages | 5 |
Journal | Current opinion in rheumatology |
Volume | 17 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2005 |
Keywords
- Muscle
- Myopathy
- Myostatin
- Regeneration
ASJC Scopus subject areas
- Rheumatology